Combining ADCs with protein degraders could widen the therapeutic windows of both

With a series of recent deals, a splashy newco debut and a second candidate poised to enter the clinic, degrader-antibody conjugates are emerging as the next contenders to build on the success of the ADC paradigm by expanding the menu of payloads. 

Combining the cell-type selectivities of an antibody vector and a degrader payload could overcome the safety hurdles each therapeutic modality faces on its own, and the strategy creates avenues for dealmaking between players who specialize in either side. ...